Xiaodong Zhou1, Yujie Li2. 1. Department of Surgical Oncology, Yuyao People's Hospital, Yuyao, China, Ningbo, China. 2. Department of Surgical Oncology, Ningbo No. 2 Hospital, Ningbo, China.
Abstract
BACKGROUND: Breast-conserving surgery (BCS) in patients with large tumors shrunk by neoadjuvant chemotherapy (NCT) remains controversial. We conducted a meta-analysis to evaluate the local recurrence rates in locally advanced breast cancer (LABC) patients receiving NCT comparing BCS with mastectomy. METHODS: Pubmed, Web of Knowledge, and Ovid's database were searched for studies concerning treatment for LABC from January 2000 to June 2015. A meta-analysis was performed to compare the recurrence rates of patients receiving BCS versus mastectomy following NCT. RESULTS: 8 trials with a total of 3,215 patients were analyzed. The prevalence of local recurrence was 9.2% in the BCS group versus 8.3% in the mastectomy group without significant difference (odds ratio (OR) 1.07, 95% confidence interval (CI) 0.28-1.48; p = 0.66). The 5-year local recurrence-free survival (LRFS) rate was lower in the mastectomy group than in the BCS group, but no significant difference was found between the 2 groups (OR 1.11, 95% CI 0.61-1.99; p = 0.74). CONCLUSION: BCS after NCT is safe in terms of local recurrence and LRFS in LABC women. Shrinking tumors with NCT provides the opportunity to apply BCS with no detriment to outcome.
BACKGROUND: Breast-conserving surgery (BCS) in patients with large tumors shrunk by neoadjuvant chemotherapy (NCT) remains controversial. We conducted a meta-analysis to evaluate the local recurrence rates in locally advanced breast cancer (LABC) patients receiving NCT comparing BCS with mastectomy. METHODS: Pubmed, Web of Knowledge, and Ovid's database were searched for studies concerning treatment for LABC from January 2000 to June 2015. A meta-analysis was performed to compare the recurrence rates of patients receiving BCS versus mastectomy following NCT. RESULTS: 8 trials with a total of 3,215 patients were analyzed. The prevalence of local recurrence was 9.2% in the BCS group versus 8.3% in the mastectomy group without significant difference (odds ratio (OR) 1.07, 95% confidence interval (CI) 0.28-1.48; p = 0.66). The 5-year local recurrence-free survival (LRFS) rate was lower in the mastectomy group than in the BCS group, but no significant difference was found between the 2 groups (OR 1.11, 95% CI 0.61-1.99; p = 0.74). CONCLUSION: BCS after NCT is safe in terms of local recurrence and LRFS in LABC women. Shrinking tumors with NCT provides the opportunity to apply BCS with no detriment to outcome.
Authors: Himanshu Nagar; Elizabeth A Mittendorf; Eric A Strom; George H Perkins; Julia L Oh; Welela Tereffe; Wendy A Woodward; Ana M Gonzalez-Angulo; Kelly K Hunt; Thomas A Buchholz; Tse-Kuan Yu Journal: Int J Radiat Oncol Biol Phys Date: 2011-08-30 Impact factor: 7.038
Authors: E Touboul; J P Lefranc; J Blondon; L Buffat; E Deniaud; Y Belkacémi; M Benmiloud; J Huart; A Laugier; M Schlienger Journal: Radiother Oncol Date: 1997-03 Impact factor: 6.280
Authors: R Rouzier; J M Extra; M Carton; M C Falcou; A Vincent-Salomon; A Fourquet; P Pouillart; E Bourstyn Journal: J Clin Oncol Date: 2001-09-15 Impact factor: 44.544
Authors: F Fitzal; O Riedl; M Mittlböck; P Dubsky; R Bartsch; G Steger; R Jakesz; M Gnant Journal: Breast Cancer Res Treat Date: 2010-09-17 Impact factor: 4.872
Authors: L Mauriac; G MacGrogan; A Avril; M Durand; A Floquet; M Debled; J M Dilhuydy; F Bonichon Journal: Ann Oncol Date: 1999-01 Impact factor: 32.976
Authors: H M Kuerer; S E Singletary; A U Buzdar; F C Ames; V Valero; T A Buchholz; M I Ross; L Pusztai; G N Hortobagyi; K K Hunt Journal: Am J Surg Date: 2001-12 Impact factor: 2.565
Authors: Allen M Chen; Funda Meric-Bernstam; Kelly K Hunt; Howard D Thames; Mary Jane Oswald; Elesyia D Outlaw; Eric A Strom; Marsha D McNeese; Henry M Kuerer; Merrick I Ross; S Eva Singletary; Fredrick C Ames; Barry W Feig; Aysegul A Sahin; George H Perkins; Naomi R Schechter; Gabriel N Hortobagyi; Thomas A Buchholz Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544